Form 4: Acrivon CLO Withholds Shares for RSU Tax (Form 4)

Chief Legal Officer Mary Miller withheld 184 ACRV shares at $2.24 to cover taxes on RSU vesting, leaving 34,555 shares owned directly.

Summary

• On 2025-11-14, Mary Miller (Chief Legal Officer of Acrivon Therapeutics, Inc., ticker ACRV) had 184 common shares withheld under transaction code F to satisfy tax withholding upon RSU vesting.
• The transaction price used for withholding was $2.24 per share.
• Following the withholding, Miller directly owns 34,555 common shares.
• This was an administrative tax withholding (not an open-market purchase or sale).
• The form was signed by Attorney-in-Fact Adam D. Levy on 2025-11-18.

Sentiment

Score: 5

Explanation: Neutral; routine administrative RSU tax withholding with minimal impact and no new information on business performance.

Positives

• Routine RSU tax withholding (Code F) rather than an open-market sale, reducing signaling risk.
• Officer continues to hold 34,555 shares after the transaction, indicating ongoing equity exposure.
• Clear disclosure of transaction price at $2.24 per share.

Negatives

• Slight reduction in direct holdings by 184 shares due to tax withholding.
• No new information on operations, financial performance, or strategic initiatives.

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Shares withheld by the issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Industry Context

Insider RSU net-share settlements for tax withholding are routine across biotech and broader public markets and typically carry limited signaling value regarding company fundamentals.

Comparison to Industry Standards

• Code F transactions for RSU tax withholding are standard practice, similar to administrative insider settlements commonly disclosed by biotech peers such as Moderna, Gilead, and Vertex.
• The small size (184 shares) is immaterial versus insider sale/purchase levels that typically influence sentiment, aligning with ordinary-course administrative events sector-wide.

Related Party Transactions

• Issuer withheld 184 shares from officer Mary Miller upon RSU vesting to satisfy mandatory tax withholding (Code F) at $2.24 per share.

Stakeholder Impact

• Minimal impact; administrative insider tax withholding with no effect on operating performance or control.
• No open-market sale; the transaction reflects net settlement of RSU-related taxes.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, insider transaction, Mary Miller, Chief Legal Officer, restricted stock units, RSU tax withholding, beneficial ownership, biotech